AptinyxLogo_FullColor_RGB.jpg
Aptinyx Completes Enrollment in Phase 2 Exploratory Study of NYX-783 in Post-Traumatic Stress Disorder
June 18, 2020 07:57 ET | Aptinyx Inc.
EVANSTON, Ill., June 18, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
AptinyxLogo_FullColor_RGB.jpg
Aptinyx Reports First Quarter 2020 Financial Results and Highlights
May 14, 2020 16:03 ET | Aptinyx Inc.
Over 90% of target enrollment achieved to date in Phase 2 exploratory study of NYX-783 in PTSD; data readout expected in late 2020 Cash balance of $121 million expected to support planned operations...
AptinyxLogo_FullColor_RGB.jpg
Aptinyx to Report First Quarter Financial Results on Thursday, May 14, 2020
April 30, 2020 08:47 ET | Aptinyx Inc.
EVANSTON, Ill., April 30, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
AptinyxLogo_FullColor_RGB.jpg
Aptinyx Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
March 30, 2020 16:01 ET | Aptinyx Inc.
Initiated four Phase 2 clinical studies based on compelling prior data Actions taken on ongoing clinical studies due to COVID-19 pandemic Strong cash position following recently completed common...
AptinyxLogo_FullColor_RGB.jpg
Aptinyx to Report Fourth Quarter and Full Year 2019 Financial Results on Monday, March 30, 2020
March 18, 2020 16:01 ET | Aptinyx Inc.
EVANSTON, Ill., March 18, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
AptinyxLogo_FullColor_RGB.jpg
Aptinyx to Present at Upcoming Investor Conferences
February 19, 2020 08:37 ET | Aptinyx Inc.
EVANSTON, Ill., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
AptinyxLogo_FullColor_RGB.jpg
Aptinyx Announces Publication of Data in Movement Disorders Demonstrating Reversal of Cognitive Deficits with NYX-458 in Primate Model of Parkinson’s Disease
January 30, 2020 07:07 ET | Aptinyx Inc.
EVANSTON, Ill., Jan. 30, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
AptinyxLogo_FullColor_RGB.jpg
Aptinyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option
January 14, 2020 16:01 ET | Aptinyx Inc.
EVANSTON, Ill., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
AptinyxLogo_FullColor_RGB.jpg
Aptinyx Initiates Phase 2 Study of NYX-458 in Patients with Mild Cognitive Impairment Associated with Parkinson’s Disease
December 05, 2019 06:58 ET | Aptinyx Inc.
Phase 2 study follows NYX-458 preclinical data demonstrating reversal of cognitive deficits in non-human primate model of Parkinson’s disease Fourth Phase 2 study initiated by Aptinyx in 2019 across...
AptinyxLogo_FullColor_RGB.jpg
Aptinyx to Present at Upcoming Investor Conferences
November 14, 2019 07:57 ET | Aptinyx Inc.
EVANSTON, Ill., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...